{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:30:10Z","timestamp":1777419010336,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2005,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To report the case of a patient affected by gastrointestinal stromal tumors (GIST) who developed cutaneous adverse drug reactions during treatment with imatinib and lansoprazole.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY:<\/jats:title>\n                    <jats:p>After 2 months of treatment with imatinib 400 mg\/day, a 60-year-old white female affected by GIST developed bilateral palpebral edema with hyperemic conjunctivae and labial edema when lansoprazole 15 mg\/day was introduced to treat dyspeptic symptomatology. Treatment was discontinued, and on reintroduction of both drugs, the patient developed Stevens\u2014Johnson syndrome. Two months later, generalized cutaneous reactions appeared immediately following reintroduction of low-dose imatinib with corticosteroid plus lansoprazole treatment. After discontinuation of all drugs, with the exception of the corticosteroid, the progression of cutaneous lesions stopped.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>The use of imatinib is commonly associated with a high dose-dependent rate of rash and edema. Several cases of Stevens\u2014Johnson syndrome have also been described, although not in patients affected by GIST. Severe skin reactions have been reported for lansoprazole including erythema multiforme, Stevens\u2014Johnson syndrome, and toxic epidermal necrolysis. Applying Naranjo's algorithm, the adverse events were considered possible due to imatinib and probable due to lansoprazole.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>On the basis of the data reported, we conclude that the adverse reactions described may be attributed to either drug alone. However, combined use of drugs may increase the risk of onset of these adverse reactions due to a potential drug interaction involving CYP3A4.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1e127","type":"journal-article","created":{"date-parts":[[2004,11,16]],"date-time":"2004-11-16T22:23:23Z","timestamp":1100643803000},"page":"162-164","source":"Crossref","is-referenced-by-count":29,"title":["Adverse Reactions During Imatinib and Lansoprazole Treatment in Gastrointestinal Stromal Tumors"],"prefix":"10.1177","volume":"39","author":[{"given":"Giovanni","family":"Severino","sequence":"first","affiliation":[{"name":"Giovanni Severino MD, Clinical Pharmacologist, Section of Clinical Pharmacology, Department of Neurosciences, B.B. Brodie, University of Cagliari, Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Chillotti","sequence":"additional","affiliation":[{"name":"Caterina Chillotti MD, Clinical Pharmacologist, Section of Clinical Pharmacology, Department of Neurosciences, B.B. Brodie, University of Cagliari and Local Health Unit 8"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"De Lisa","sequence":"additional","affiliation":[{"name":"Roberto De Lisa MD, Resident Specialist, Section of Clinical Pharmacology, Department of Neurosciences, B.B. Brodie, University of Cagliari"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Del","family":"Zompo","sequence":"additional","affiliation":[{"name":"Maria Del Zompo MD, Full Professor; Director, Section of Clinical Pharmacology, Department of Neurosciences, B.B. Brodie, University of Cagliari and ASL 8"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Ardau","sequence":"additional","affiliation":[{"name":"Raffaella Ardau MD, Clinical Pharmacologist, Section of Clinical Pharmacology, Department of Neurosciences, B.B. Brodie, University of Cagliari and ASL 8"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2005,1,1]]},"reference":[{"key":"bibr1-aph.1E127","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)80600-1"},{"key":"bibr2-aph.1E127","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200108233450814"},{"key":"bibr3-aph.1E127","unstructured":"3 Package insert. Prevacid (lansoprazole). www.fda.gov\/medwatch\/SAFETY\/2003\/03AUG_PI\/Prevacid_PI.pdf (accessed 2004 Feb 11)."},{"key":"bibr4-aph.1E127","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7230.283"},{"key":"bibr5-aph.1E127","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06535-7"},{"key":"bibr6-aph.1E127","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020461"},{"key":"bibr7-aph.1E127","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00836-5"},{"key":"bibr8-aph.1E127","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.44"},{"key":"bibr9-aph.1E127","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03499.x"},{"key":"bibr10-aph.1E127","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2431"},{"key":"bibr11-aph.1E127","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D184"},{"key":"bibr12-aph.1E127","first-page":"853","volume":"25","author":"Ko JW","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"bibr13-aph.1E127","unstructured":"13 Electronic Medicines Compendium (2003): emc.medicines.org.uk (accessed 2004 Feb 11)."},{"key":"bibr14-aph.1E127","first-page":"825","volume":"299","author":"Dai D","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr15-aph.1E127","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1E127","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1E127","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1E127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:08:59Z","timestamp":1777374539000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1E127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["10.1345\/aph.1E127"],"URL":"https:\/\/doi.org\/10.1345\/aph.1e127","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}